Home » News » Significant Refundable R&D Offsets Receipts Reported to the ASX in Recent Months

Significant Refundable R&D Offsets Receipts Reported to the ASX in Recent Months

Over recent months, a number of companies have reported to the ASX receipt of substantial Refundable R&D Tax Offsets.

Notable receipts include:

• Syntara Limited (ASX: SNT) reported a $5.25 million Refundable R&D tax offset related to its clinical development pipeline including PXS-5505 in myelofibrosis project;
• Neurotech International (ASX: NTI) reported a $3.17 million Refundable R&D tax offset related to its development of treatments for paediatric neurological disorders
• ClearVue Technologies Limited (ASX:CPV) reported a $0.94 million Refundable R&D tax offset related to its Smart building materials development
• Mighty Kingdom (ASX: MKL) reported a $1.89 million Refundable R&D tax offset related to its digital game development activities;
• Trigg Minerals (ASX: TMG) reported a $1.31 million Refundable R&D tax offset related to its sulphate of potash project;
• FYI Resources (ASX: FYI) reported a $1.2 million Refundable R&D tax offset related to its HPA developments;
• Anteris Technologies Ltd (ASX:AVR) reported a $1.4 million Refundable R&D tax offset related to its ADAPT®, DurAVR™ and ComASUR™ medical technologies;
• Dimerix Limited (ASX:DXB) reported a $8.9 million Refundable R&D tax offset related to its Phase 3 FSGS kidney disease trial;

The diversity of companies and projects receiving reviews evidences a key benefit of the R&D Tax Incentive being a broad based, market driven system.

Receipt of a tax offsets reduce the need for a company to raise additional capital to complete trials or further R&D, and could make pathway to commercialisation exponentially easier.

Please get in touch with our office if you would like to speak to someone about a potential claim, or check out our website for more information.